Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

STAR Study Investigating Performance and Safety of the Medical Device SiPore15™

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03823027
Recruitment Status : Recruiting
First Posted : January 30, 2019
Last Update Posted : March 4, 2019
Sponsor:
Information provided by (Responsible Party):
Sigrid Therapeutics AB

Brief Summary:
The primary objective of STAR01 is to evaluate the performance and safety of the medical device (class IIb) SiPore15™ after a 12-week long treatment in the target population of obese and overweight subjects with prediabetes or newly diagnosed type 2 diabetes. The expected performance and safety of the device is based on the safety and efficacy results seen in an earlier First-in-Man (FIM) study. The safety and tolerability of SiPore15™ is based on the well-established and extensive use of food grade silicon dioxide and favorable data from the FIM study. Data on side-effects will be collected for verification of device safety. The study duration is 24 weeks in total, 12 weeks from baseline on investigational medicinal device (IMD) treatment, with additional 12 weeks off treatment. The study population is planned for forty (40) subjects to be enrolled, male and females, age >18 years and fulfilling all inclusion criteria but none of the exclusion criteria.

Condition or disease Intervention/treatment Phase
PreDiabetes Pre Diabetes Prediabetic State Type2 Diabetes Type2 Diabetes Mellitus Overweight Obese Device: SiPore15™ Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Intervention Model Description: The single-arm study is designed to collect data on changes over time, i.e. comparing the pre-treatment/baseline value with the value achieved after full treatment (12 weeks). Thus, each individual act as his/her own control. The study design has been discussed with notified bodies, and deemed appropriate as there is no state-of-the-art pharmacotherapy for treatment of prediabetes to compare with.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Single-arm, Multicenter Study Investigating Performance and Safety of SiPore15™ in Obese and Overweight Subjects With Prediabetes or Newly Diagnosed Type 2 Diabetes
Actual Study Start Date : January 28, 2019
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prediabetes

Arm Intervention/treatment
Experimental: Single-arm
The device will be taken before three daily main meals togteher with water. The dose will be escalated from 1g per main meal to the full dose of 3g per main meal. The device is provided in foil stick-packs packed in boxes with weekly supply. The treatment is for 12 weeks.
Device: SiPore15™
SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.




Primary Outcome Measures :
  1. Performance measured as changes in HbA1c [ Time Frame: From week 1 to week 12 ]
    To measure change in long-term blood glucose levels, HbA1c, from baseline (week 1) to end- -of-treatment (week 12).

  2. Tolerability measured as evaluation of Adverse Events [ Time Frame: From week 1 to week 14 ]
    To assess safety and tolerability by evaluating the frequency and incidence of both adverse events (AEs) and device related adverse events (ADEs) during the study treatment and follow-up, from baseline (week 1) until week 14.


Secondary Outcome Measures :
  1. Performance measured as changes in LDL-C [ Time Frame: From week 1 to week 12 ]
    To measure change in LDL-C blood levels from baseline (week 1) to week 6 and end-of- treatment (week 12).

  2. Performance measured as changes in body fat % [ Time Frame: From week 1 to week 12 ]
    To measure change in body fat levels (bio electric impedance, BIA) from baseline (week 1) to week 6 and end-of-treatment (week 12).


Other Outcome Measures:
  1. Exploratory Endpoint on Medical Device Usability [ Time Frame: From week 1 to week 12 ]

    To assess Medical Device Usability by collecting data:

    a. Collect information on Ease of use (Easy, neither/nor, difficult) at visit week 2, 6 and end-of -treatment.


  2. Explorative Endpoint on changes in Cholesterol [ Time Frame: From week 1 to week 12 ]
    To measure change in total Cholesterol levels from baseline to week 6 and end-of-treatment.

  3. Explorative Endpoint on changes in microbiome diversity (species not defined) [ Time Frame: From week 1 to week 24 ]
    To explore changes in microbiome by feces sampling for research at baseline and at week 24.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 105 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent form.
  2. Male or female aged ≥18 years on the day of screening.
  3. Female subjects of childbearing potential must be on non-oral contraceptives, postmenopausal or sterile.
  4. Prediabetes or newly diagnosed T2D (not on blood sugar lowering drugs) defined as HbA1c levels: ≥42 to ≤57 mmol/mol (≥6.0 to ≤7.5%-according to DCCT).
  5. Body mass index (BMI) >25 kg/m2 and > or = 40 kg/m2.
  6. Stable weight for 3 months (+/-5 kg).
  7. No extreme changes in diet for the last 6 months such as anorexia, bulimia, etc.
  8. Subject must be able and willing to attend all scheduled visits and comply with all study procedures with no planned holiday longer than 2 weeks during the 12 weeks of treatment.

Exclusion Criteria:

  1. Diagnosed with type1 diabetes/Latent Autoimmune Diabetes in Adult (LADA) or secondary diabetes, as part of medical history or confirmed by laboratory test.
  2. Previous or current Metformin treatment or other glucose reducing drug therapy within 3 months before screening visit.
  3. Previous or current statin treatment or other blood lipid (LDL) reducing drug therapy, within 12 months before screening visit.
  4. Previous or current medication known to cause weight loss or weight gain, such as systemic corticosteroids, thyroid hormones or Estrogen, within 1 month before screening visit.
  5. Subjects who stopped smoking within 6 months before screening visit.
  6. Diagnosed with chronic somatic diseases, except for obesity and treatment naive T2D, that in the opinion of the investigator may therefore affect metabolic and /or intestinal function (e.g. inflammatory bowel disease, intestinal dysfunction, pancreatic dysfunction, other causes of malabsorption, recent (past 6 months) neoplastic disease.
  7. Any history of myocardial infarction or stroke within the 6 months before screening visit.
  8. Anemia, donated blood or other major blood loss within 3 months from screening visit that in the opinion of the clinician may interfere with the study.
  9. Pregnancy or breast feeding.
  10. Allergies to silicon dioxide.
  11. A diagnosed state that requires use of vitamin and/or mineral supplements during the study.
  12. Previous major gastric surgery that may affect the study outcome, such as bariatric surgery.
  13. Ongoing or unstable kidney condition with moderate to great reduction in glomerular filtration rate < 90 ml/min (GFR) that may affect metabolic parameters during the trial.
  14. Ongoing or unstable liver condition that may cause changes in liver enzymes exceeding 2x upper normal levels.
  15. Psychiatric or cognitive disorder and/or behavioral problems which in the opinion of the clinician may interfere with the study.
  16. History of or ongoing alcohol or drug addiction.
  17. Participation in any study involving an investigational drug or medical device within the past 30 days before the screening visit.
  18. Belongs to a vulnerable population or has any condition such that his/her ability to provide informed consent, comply with the follow-up requirements, or provide self- assessments is compromised (e.g. homeless, developmentally disabled and prisoner).
  19. Is a relative of the Investigator or an employee at the clinical study site.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03823027


Contacts
Layout table for location contacts
Contact: Kirsi Pietiläinen, Prof. +358 (0) 2941 911 kirsi.pietilainen@helsinki.fi

Locations
Layout table for location information
Finland
Pihlajalinna Ite, Satucon OY Recruiting
Kuopio, Finland, 70100
Contact: Sakari Nieminen, MD       sakari.nieminen@satucon.fi   
Contact: Laura Jääskeläinen, Nurse    +358 40 774 1104    tutkimukset@satucon.fi   
Sweden
Clinical Trial Consultants Recruiting
Uppsala, Uppland, Sweden, 752 37
Contact: Erik Rein-Hedin, MD       erik.rein-hedin@ctc-ab.se   
Contact: Gabriella Seger, Nurse    +46 72 3659087    gabriella.seger@ctc-ab.se   
Sponsors and Collaborators
Sigrid Therapeutics AB
Investigators
Layout table for investigator information
Study Chair: Kirsi Pietiläinen, Prof. Gyllenberg Professor in Clinical Metabolism Obesity Research Unit University of Helsinki

Additional Information:
Layout table for additonal information
Responsible Party: Sigrid Therapeutics AB
ClinicalTrials.gov Identifier: NCT03823027     History of Changes
Other Study ID Numbers: STAR01
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: March 4, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sigrid Therapeutics AB:
Medical Device
Prediabetes
Type2 Diabetes
Silica
Metabolic risk factors

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Overweight
Prediabetic State
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Body Weight
Signs and Symptoms
Hyperglycemia